Long-term safety of topical calcitriol 3 μg g−1 ointment

doi:10.1046/j.1365-2133.2001.144s58017.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

British Journal of Dermatology

Volume 144 Issue s58, Pages 17 - 19

Published Online: 28 Jun 2008

An Official Journal of the British Association of Dermatologists

Go to Society Site

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: HTML, PDF (Size: 67K) | Related Articles | Citation Tracking

Long-term safety of topical calcitriol 3 μg g⁻¹ ointment

M.J.P. Gerritsen ¹ , P.C.M. van de Kerkhof ¹ & A. Langner ²

¹ Department of Dermatology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands ² Dermatology Department, Medical University of Warsaw, Poland

Correspondence to: Dr. M. Gerritsen

KEYWORDS

calcitriol • long-term • plaque psoriasis • safety • tolerance

ABSTRACT

To assess the topical and systemic safety and tolerance of twice-daily application of 3 μg g⁻¹ 1α25-dihydroxyvitamin D₃ (calcitriol) ointment (Silkis ointment®, Galderma Laboratories) in the long-term treatment of patients suffering from chronic plaque psoriasis, we performed an open-design, multicentre study. Two hundred and fifty-three patients (155 males, 98 females) treated all their psoriatic lesions, except for those on the head and scalp, for up to 78 weeks. No serious adverse events were reported; 37 patients (14·6%) had a transient skin irritation reaction on one or more occasions during the study that resulted in study withdrawal for seven of them. The baseline/endpoint analyses showed no clinically relevant changes in measures of calcium and phosphorus homeostasis and renal function. Slight hypercalcaemia was observed in five (2%) patients; in four of these patients, serum albumin-adjusted total calcium levels normalized during treatment. In conclusion, twice-daily calcitriol 3 μg g⁻¹ ointment is safe and well tolerated in the long-term treatment of chronic plaque psoriasis.

DIGITAL OBJECT IDENTIFIER (DOI)

10.1046/j.1365-2133.2001.00035.x About DOI